Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- (Update) Add’l Eligibility Criteria Proposed for Companies to Get Price Maintenance Premium, Tiered Premiums Eyed: Chuikyo
June 15, 2017
- Chuikyo OKs Plan for FY2017 Drug Price Survey
June 14, 2017
- Add’l Eligibility Criteria Proposed for Companies to Get Price Maintenance Premium: Chuikyo
June 14, 2017
- PMDA Provides Relief for Over 100 Health Damage Cases Tied to HPV Vaccines: FY2016
June 13, 2017
- MHLW Panel Gives Thumbs-Up for Nusinersen, Tenelia-Canaglu Combo
June 12, 2017
- MHLW Study Group on Counterfeit Drugs to Discuss Issues such as GDP Later This Fiscal Year
June 12, 2017
- Govt’s Regulatory Reform Plan Embraces Review of 14-Day Prescription Limit
June 12, 2017
- MHLW Study Group Compile Draft Interim Report on Preventing Distribution of Counterfeit Drugs
June 12, 2017
- Japan Cabinet Adopts 2017 Honebuto Policy
June 12, 2017
- MHLW Issues Notification on New Format for Package Inserts
June 9, 2017
- MHLW Study Puts Global Biosimilar Market at 1-3 Trillion Yen in 2020
June 8, 2017
- Govt to Erase Reference Pricing from Honebuto Policy, though Proposal Still Alive
June 8, 2017
- Tweaking Likely for Honebuto Wording on Reference Pricing, Integration of Gx Price Bands
June 7, 2017
- Avastin’s Orphan Status Withdrawn for Pleural Mesothelioma
June 6, 2017
- MEXT to Consider Company Payment Probe for Private Univ. Hospitals: Official
June 5, 2017
- Inject Intensive Resources for Healthy Lifespan Extension: Honebuto Draft
June 5, 2017
- Draft Honebuto Policy OK’ed by CEFP, Says Distinguish “Me Too” Drugs from Pioneering Meds
June 5, 2017
- MHLW Mulling to Add Clinical Trial Data for Generic Labels
June 2, 2017
- 4 Eligibility Criteria Presented for Conditional Early Approval System
June 2, 2017
- 3rd Sakigake Invitation for Drugs Slated for This Autumn: MHLW
June 2, 2017
ページ
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…